LJPC La Jolla Pharmaceuticals did a reverse stock split and uplist. Ran to $45 per share and is now back down to $12 per share but the drop has to do with market prospects, and bad market selling.
ADXS did a large stock split from .04 cents per share to $4 or $5 per share I think it was a 1 for 200 r/s or something like that. Anyways on good news it ran to $30 per share now down to .20 cents per share.
The point is those companies ran higher after doing a reverse stock split and uplisting to NASDAQ. You can check the history at those times when they did the uplist and r/s they did so when there was no phase 3 done and no FDA approval yet.
Cytoydn has already completed a combination phase 3, and ready to file a BLA. Plus it is near on possibly finishing up the monotherapy as well with a label expansion.
News 
Market Data 
Discover 
